Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
The Wellcome Sanger Institute
Immunocore Ltd
Centre Oscar Lambret
Emory University
Endeavor Biomedicines, Inc.
University Hospital, Caen
University of Miami
University Hospital Erlangen
Massachusetts Eye and Ear Infirmary
Institut Curie
Thomas Jefferson University
Vastra Gotaland Region
Institut Curie
Institut Curie
Institut Curie
HonorHealth Research Institute
Institut Curie
Institut Curie
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Grupo Español Multidisciplinar de Melanoma
Seagen Inc.
Thomas Jefferson University
University Hospital, Essen
Vastra Gotaland Region
Centre Hospitalier Universitaire de Nice
Aura Biosciences
Centre Hospitalier Universitaire de Nice
Charite University, Berlin, Germany
University of Michigan Rogel Cancer Center
University of Virginia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aura Biosciences
Institut Curie
Delcath Systems Inc.
Vastra Gotaland Region
Columbia University
Perspective Therapeutics
University of Florida
Columbia University
Columbia University
OHSU Knight Cancer Institute
Viralytics
Immunocore Ltd
Hoffmann-La Roche